Osilodrostat
VIDEO: Data shed new light on treatments for acromegaly, Cushing’s disease
BOSTON — In this video exclusive, Maria Fleseriu, MD, FACE, discusses some of the top adrenal and pituitary news from ENDO 2024.
Osilodrostat improves comorbid hypertension, diabetes for adults with Cushing’s disease
BOSTON — Long-term osilodrostat therapy may improve symptoms of comorbid cardiometabolic disorders such as hypertension and diabetes for adults with Cushing’s disease, according to data presented at ENDO 2024.
Addressing glucocorticoid withdrawal syndrome in treatment of Cushing’s syndrome
To achieve optimal outcomes in Cushing’s syndrome, both clinicians and patients need to be prepared for the type and duration of symptoms that patients may experience during treatment and recovery.
Osilodrostat normalizes urinary free cortisol in Cushing’s disease for most at 72 weeks
More than 80% of adults with Cushing’s disease receiving osilodrostat had normalized mean urinary free cortisol levels at 72 weeks of treatment, according to findings from the LINC 3 study extension.
Osilodrostat improves physical manifestations of hypercortisolism for most adults
SAN DIEGO — Osilodrostat is associated with improvements in physical manifestations of hypercortisolism and reductions in mean body weight and BMI in adults with Cushing’s syndrome, according to a speaker.
Osilodrostat normalizes urinary free cortisol in most adults with Cushing’s disease
More than three-quarters of adults with Cushing’s disease assigned osilodrostat had a normalized mean urinary free cortisol level at 12 weeks and maintained a normal level at 36 weeks, according to data from the LINC 4 phase 3 trial.